Executive and director cash bonuses approved at Microbot Medical (NASDAQ: MBOT)

Rhea-AI Filing Summary

Microbot Medical Inc. disclosed that its board’s Compensation Committee approved special one-time cash bonuses for several executives and non‑management directors. CEO, President and Chairman Harel Gadot received $158,115, CTO Simon Sharon received approximately $64,200, and executive officer Rachel Vaknin received approximately $32,500. The committee also authorized one-time cash payments of $30,000 to $45,000 for each non‑management board member.

The committee noted that these payments reflect, in part, that the executives had previously waived 30–50% of their prorated 2023 base salaries under the company’s May 2023 cost restructuring plan.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Understanding 8-K Material Events →

false 0000883975 0000883975 2025-09-17 2025-09-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 17, 2025

MICROBOT MEDICAL INC.

(Exact name of registrant as specified in its charter)

Delaware		000-19871		94-3078125
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

175 Derby St., Bld. 27

Hingham, MA 02043

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		MBOT		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 17, 2025, Microbot Medical Inc. (the “Company”) granted special one-time cash bonuses to certain of its executive officers, as follows:

	●	Harel Gadot, the Company’s CEO, President and Chairman, received $158,115;
	●	Simon Sharon, the Company’s CTO, received approximately $64,200; and
	●	Rachel Vaknin, the Company’s CEO, received approximately $32,500.

In making the determination to grant such bonuses, the Compensation Committee of the Board of Directors of the Company (the “Compensation Committee”) considered in part that each of the executives waived between 30-50% of their prorated annual base salary in part of 2023, as part of the Company’s May 2023 cost restructuring plan.

In addition, the Compensation Committee approved an amendment to the Company’s compensation package for the non-management members of its Board of Directors (the “Board”), and authorized one-time cash payments to each of the Company’s non-management members of the Board of between $30,000 and $45,000.

(d) Exhibits.

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MICROBOT MEDICAL INC.
	By:	/s/ Harel Gadot
	Name:	Harel Gadot
	Title:	Chief Executive Officer, President and Chairman

Date: September 19, 2025

FAQ

What executive bonuses did Microbot Medical (MBOT) approve in this 8-K?

Microbot Medical approved special one-time cash bonuses for certain executives, including $158,115 for Harel Gadot, approximately $64,200 for Simon Sharon, and approximately $32,500 for Rachel Vaknin.

Why did Microbot Medical (MBOT) grant these one-time cash bonuses?

The Compensation Committee considered that the executives had waived 30–50% of their prorated 2023 annual base salaries as part of Microbot Medical’s May 2023 cost restructuring plan.

How were Microbot Medical’s non-management directors compensated in this filing?

The Compensation Committee approved an amendment to the compensation package for non‑management directors and authorized one-time cash payments of between $30,000 and $45,000 for each non‑management board member.

Which Microbot Medical (MBOT) executives are named in the bonus awards?

The executives named are Harel Gadot (CEO, President and Chairman), Simon Sharon (CTO), and Rachel Vaknin, each receiving a special one-time cash bonus in differing amounts.

Does this 8-K from Microbot Medical (MBOT) involve any stock or option grants?

The disclosure focuses on cash bonuses and one-time cash payments to executives and non‑management directors; it does not describe stock or option grants in the provided content.

What role did the Compensation Committee play in Microbot Medical’s new payments?

The Compensation Committee of the Board approved the special one-time cash bonuses for executives and amended the compensation package for non‑management directors by authorizing the one-time cash payments.